The ferritin testing market was valued at US$ 372.05 million in 2019 and is projected to reach US$ 556.19 million by 2027; it is expected to grow at a CAGR of 5.3% from 2020 to 2027. Growing burden of iron deficiency disorders and increasing prevalence of iron deficiency in aging population are among the major factors fueling the growth of this market. Moreover, government initiatives to reduce anemia worldwide is expected to foster the market growth during the forecast period. However, the availability of advanced technologies hinders the growth of the ferritin testing market. Additionally, the APAC countries are facing challenges due to the rising prevalence of COVID-19. The supply chain disruption, along with the enormous demand for effective therapies for the treatment of COVID-19, has put healthcare research industry in critical situation in APAC. The COVID-19 crisis is expected to increase micronutrient malnutrition, including anemia due to the disruption of health services with rising economic crisis affecting ongoing malnutrition programs, which is expected to negatively impact demand for ferritin testing during the forecast period. The global ferritin testing market is segmented by indication and end user.Based on indication, the market is segmented into anemia, hemochromatosis, pregnancy, and lead poisoning.
The anemia segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR during the forecast period.Based on end user, the ferritin testing market is segmented into hospitals, diagnostic laboratories, and specialty clinics.
The hospitals segment held the largest share of the market in 2019; however, the diagnostic laboratories segment is anticipated to register the highest CAGR during the forecast period. The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and the United Nations Children’s Fund (UNICEF) are among the primary and secondary sources referred while formulating this report.
Our reports have been used by over 10K customers, including:
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Step by step: An aging US population and a rising prevalence of diabetes are expected to boost industry demand Abstract Podiatrists in the US Over the five years to 2019, the Podiatrists industry has stepped in the right direction. Revenue growth has been supported by the aging US population and the...
The North America human microbiome market is expected to reach US$ 446.39 Mn in 2025 from US$ 113.88 in 2017. The market is estimated to grow with a CAGR of 21.5% from 2018-2025. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological...
The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017. The market is estimated to grow with a CAGR of 22.8% from 2018-2025. The growth of the market is driven by the factors such as rising chronic disease due to change in lifestyle and growing interest in human microbiome treatment approach....
The global human microbiome market is expected to reach US$ 1,197.08 Mn in 2025 from US$ 257.30 Mn in 2017. The market is estimated to grow with a CAGR of 21.8% from 2018-2025. The increasing incidence of lifestyle diseases are expected to fuel the market growth during the forecast period.As per World health organization in 2016, 13% of...
108 pages •
By Infiniti Research Limited
• May 2018
About Pathology Consumables Pathology consumables are laboratory commodities used for the preparation of cell or tissue samples to identify abnormalities in the sample. Technavio’s analysts forecast the Global Pathology Consumables Market to grow at a CAGR of 6.85% during the period 2018-2022. Covered...
With a population of more than 1 billion, China is the world’s largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro...
In Vitro Diagnostics
Point Of Care Testing
Infectious Disease
Pathology
Laboratory
China
Health Expenditure
Urban Population
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.